GDF-8 inhibitors

Patent metadata

Field	Value
Publication number	US-9878992-B2
Application number	US-201715366981-A
Country	US
Kind code	B2
Filing date	Jul 13, 2017
Priority date	Oct 5, 2012
Publication date	Jan 30, 2018
Grant date	Jan 30, 2018

Abstract

Described are GCF-8 inhibitors of the formula (I),

and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 5 , R 6 , X and Z are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for inhibiting GDF-8 in a cell and methods for treating a patient suffering from a disease or disorder, wherein the patient would therapeutically benefit from an increase in mass or strength of muscle tissue.

First claim

The invention claimed is:

1. A compound of the structural formula

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 wherein the salt is a pharmaceutically acceptable salt is the formic acid salt.

Assignees

• Rigel Pharmaceuticals Inc

Inventors

• Bhamidipati Somasekhar
• Gelman Marina
• Ding Pingyu
• Singh Rajinder
• Clough Jeffrey
• Kinsella Todd
• Payan Donald

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P5/48

  of the pancreatic hormones · CPC title

• A61P5/24

  of the sex hormones · CPC title

• A61P5/44

  Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids · CPC title

• A61P5/18

  of the parathyroid hormones · CPC title